The University of Kentucky Public Relations and Strategic Communications Office provides a weekly health column available for use and reprint by news media. This week's column is by Gaurang Vaidya, M.D., a UK HealthCare cardiologist specializing in advanced heart failure and heart transplantation.
LEXINGTON, Ky. (Oct. 25, 2021) — Cardiac amyloidosis is considered rare.
It is estimated to affect less than 200,000 people in the United States. With improvement in diagnostic methods, more heart failure patients are now being realized to have an underlying cardiac amyloidosis.
Cardiac amyloidosis occurs when an abnormal protein — called amyloid — builds up in your heart tissue. This build-up makes it hard for your heart to work the way it should. The heart muscles become rigid, which prevents the muscles from relaxing between beats. This prevents blood from getting into your heart.
There are two main types of cardiac amyloidosis: transthyretin (ATTR) amyloidosis or light chain (AL) amyloidosis. ATTR amyloidosis results from mutated deposits of transthyretin, a protein made by the liver. The two subtypes of ATTR are wild-type amyloidosis, which generally affects people in their 60s or older; and hereditary amyloidosis, which runs in families and typically affects people in their 40s and older. AL amyloidosis is associated with blood cancers, like multiple myeloma. It is not a type of cancer, but it is treated with chemotherapy.
Besides medication, a heart transplant is typically the most effective solution; however, most patients are not candidates because of age and/or medical history.
Research is still ongoing and many patients who were previously diagnosed with heart failure are now being realized to have underlying cardiac amyloidosis as the cause of their heart failure. It is important to make this distinction because treatment for cardiac amyloidosis is completely different and some of the regular heart failure medications are actually harmful in amyloidosis patients. On the other hand, the current treatment for cardiac amyloidosis have been shown to prolong life and preserve quality of life. The only stipulation being the requirement to start these medications early in the course of disease.
UK HealthCare’s cardiac amyloidosis clinic is the only one of its kind in Kentucky.
Patients who seek treatment through the UK HealthCare cardiac amyloidosis clinic are cared for by a team of doctors who specialize in treating cardiac amyloidosis as well as kidney, liver and other organ problems that can come with it. Nurse coordinators will support and guide patients through their care. The clinic can also connect patients with clinical trials that test new therapies and study how the disease progresses. Additionally, the clinic has nuclear pyrophosphate scan technology, which is highly accurate to diagnose cardiac amyloidosis.
The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.